SARS-CoV-2 (COVID-19) has today multiplied globally and various governments are attempting to stop the outbreak of the disease escalation into a worldwide health crisis. At this juncture, readiness, candor, clarity, and partaking of data are of paramount importance to speed up factual evaluation and starting pattern control activities, including serendipitous findings. Owing to the involvement of COVID-19, many facts regarding virulence, pathogenesis, and the real viral infection source and/or transmission mode still need to be addressed. The infected patients often present clinical symptoms with fever, dyspnea, fatigue, diarrhea, vomiting, and dry cough, as well as pulmonary, infiltrates on imaging. Extensive measures to decrease person-to-person transmission of COVID-19 are being implemented to prevent, recognize, and control the current outbreak as it is very similar to SARS-CoV in its clinical spectrum, epidemiology, and pathogenicity. In response to this fatal disease and disruptive outbreak, it is extremely vital to expedite the drug development process to treat the disease and vaccines for the prevention of COVID-19 that would help us defeat this pandemic expeditiously. This paper sums up and unifies the study of virological aspects, disease transmission, clinically administered techniques, therapeutics options, managements, future directions, designing of vaccines, and news dissemination pertaining to COVID-19.

No abstract

No abstract

Today, MXenes with fascinating electronic, thermal, optical, and mechanical features have been broadly studied for biomedical applications, such as drug/gene delivery, photothermal/photodynamic therapy, antimicrobials/antivirals, sensing, tissue engineering, and regenerative medicine. In this context, various MXene-polymer composites have been designed to improve the characteristics such as physiological stability, sustained/controlled release behaviors, biodegradability, biocompatibility, selectivity/sensitivity, and functionality. Chitosan with advantages of ease of modification, biodegradability, antibacterial activities, non-toxicity, and biocompatibility can be considered as attractive materials for designing hybridized composites together with MXenes. These hybrid composites ought to be further explored for biomedical applications because of their unique properties such as high photothermal conversion efficiency, improved stability, selectivity/sensitivity, stimuli-responsiveness behaviors, and superior antibacterial features. These unique structural, functional, and biological attributes indicate that MXene-chitosan composites are attractive alternatives in biomedical engineering. However, several crucial aspects regarding the surface functionalization/modification, hybridization, nanotoxicological analyses, long-term biosafety assessments, biocompatibility, in vitro/in vivo evaluations, identification of optimization conditions, implementation of environmentally-benign synthesis techniques, and clinical translation studies are still need to be examined by researchers. Although very limited studies have revealed the great potentials of MXene-chitosan hybrids in biomedicine, the next steps should be toward the extensive research and detailed analyses in optimizing their properties and improving their functionality with a clinical and industrial outlook. Herein, recent developments in the use of MXene-chitosan composites with biomedical potentials are deliberated, with a focus on important challenges and future perspectives. In view of the fascinating properties and multifunctionality of MXene-chitosan composites, these hybrid materials can open significant new opportunities in the future for bio- and nano-medicine arena.

Recent studies have shown that several children diagnosed with COVID-19 have developed Kawasaki Disease (KD)-like symptoms. This systematic review aims to assess the demographic, laboratory, and clinical characteristics of children with KD-like syndrome during the COVID-19 pandemic and evaluate efficacy of treatments and patients' outcome. A comprehensive search was carried out systematically through PubMed, Scopus, and Web of Science (WoS), medRxiv, and bioRxiv by two reviewers independently for all studies or preprints data on the demographic, laboratory, and clinical characteristics of children with K.D-like signs during the COVID-19 outbreak. Overall, 378 studies were identified by the systematic search, of which 25 studies were included in the study. The included studies involved 599 patients in total. Thirteen studies (52%) were case reports or case series, and the rest (48%) were cohort studies. In 19 studies, patients were diagnosed with Multisystem inflammatory syndrome in children (MIS-C). In 16 studies COVID-19 was diagnosed in all patients based on their polymerase chain reaction result, serological findings, and computed tomography results. Higher C-reactive protein and erythrocyte sedimentation rate level were the most prevalent laboratory findings. In most studies, patients had leucopenia with marked lymphopenia, hypoalbuminemia, and increased ferritin, as well as hyponatremia. Abnormal echocardiography and respiratory outcomes were the most common clinical outcomes. In 11 studies, all patients required intensive care unit admission. Findings of the present systematic review show that the incidence of KD-like syndrome in the COVID-19 pandemic increased significantly. Moreover, this study offers new insights in the KD-like syndrome pathogenesis and clinical spectrum during COVID-19 pandemic.